Table 1

Characteristics of studies included in the meta-analysis

Author

Year

Study Design

SJS/TEN Casesa

(n)

Controls

Data Collection

Specific Requirement for Case Allopurinol-Exposureb

Matching Criteria

NOS


Matched

(n)

Population

(n)

SJS/TEN Cases

Controls


Hung SI [10]

2005

Case-control

21

135

93c

R

R

Yes

Drug, hospital

7

Kaniwa N [11]

2008

Case-population controld

10

-

493e

R

-

NR

-

3

Lonjou C [12]

2008

Case-population controld

31

-

1822f

R (N = 70), P (N = 80)

-

Yes

-

3

Tassaneeyakul W [13]

2009

Case-controlg

27

54

-

R

R

Yes

Drug, hospital

7

Kang HR [14]

2011

Case-control

5

57

485h

R

R

Yes

Drug, hospital

4

Jung JW [15]

2011

Retrospective cohort

2

432

485h

R

R

Yes

Drug, hospital

6


Abbreviation: R = retrospective, P = prospective, NOS = Newcastle-Ottawa Scale, NR = not report

a Only patients that received drugs of interest (Allopurinol) were included.

b Including: maximum time to develop adverse drug reaction (ADR) from drug initiation [10,12,13], improvement of symptom upon drug discontinuation [10,13], and exclusion of patients without symptoms upon re-exposure [10].

c Healthy subjects randomly selected from a biobank under nationwide population study, in which 3312 Han Chinese descendants were recruited based on the geographic distribution across Taiwan. There was no self-report of adverse drug events by any of the population control.

d Using population based as control group.

e Data of healthy Japanese reported by Tanaka H, et al. [20].

f Using allele frequencies from European populations available on dbMHC: http://www.ncbi.nlm.nih.gov/projects/mhc/ihwg.cgi webcite

g Author described the study as cross-sectional case-control study.

h Using allele frequency from the general population of Korea.

Somkrua et al. BMC Medical Genetics 2011 12:118   doi:10.1186/1471-2350-12-118

Open Data